Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02512926 · ClinicalTrials.gov registry record · Phase 1
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
A Phase 1 study of Refractory Solid Tumors and Refractory Leukemia, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 8
- Study locations
NCT02512926 is a Phase 1 study of Refractory Solid Tumors and Refractory Leukemia that has completed, run by Stanford University. The registered enrollment target is 4 participants, below the 1,467-participant average among 7 other Refractory Solid Tumors trials with a reported enrollment target (100% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT02512926, a Phase 1 study of Refractory Solid Tumors and Refractory Leukemia, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumors or leukemia. Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Etoposide
- DRUG Carfilzomib
Study Locations (8)
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
California
- Stanford University School of Medicine and Stanford Cancer Institute - Palo Alto
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan-Kettering Cancer Center - New York
Pennsylvania
- Penn State Hershey Children's Hospital - Hershey
Texas
- University of Texas Health Science Center at San Antonio - San Antonio
Alberta
- Alberta Children's Hospital - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-02-16 |
| Est. Completion | 2023-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02512926
The ClinicalTrials.gov registry entry for NCT02512926 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,467-participant average among 7 other Refractory Solid Tumors trials with a reported enrollment target (100% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Refractory Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT02512926 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Arizona, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT02512926 about?
NCT02512926 is a clinical study titled "Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children". This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumo...
What is the current status of trial NCT02512926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2016-02-16. Estimated completion is 2023-11-07.
What conditions does trial NCT02512926 study?
This clinical trial studies the following conditions: Refractory Solid Tumors, Refractory Leukemia, Relapsed Leukemia, Relapsed Solid Tumors.
What interventions are being tested in trial NCT02512926?
The interventions under investigation include: Cyclophosphamide (DRUG), Etoposide (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT02512926?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02512926 being conducted?
This trial has 8 study locations across Arizona, Arkansas, California, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RECRUITING · Phase 1
-
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
RECRUITING · Phase 1
-
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
COMPLETED · Phase 1
-
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
COMPLETED · Phase 1
-
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
COMPLETED · Phase 1
-
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.